1.Clinical observation on treatment of hypertension (yin-deficiency with sthenic-yang syndrome type) with Zhongfu Hypotension Capsule.
Qiu-ai KOU ; Hua-ping YU ; Guo-dong ZHOU
Chinese Journal of Integrated Traditional and Western Medicine 2007;27(8):745-748
OBJECTIVETo observe the efficacy and safety of zhongfu hypotension capsule (ZHC) in treating hypertension of yin-deficiency with sthenic-yang syndrome type.
METHODSAdopting the stratified, block randomized, double-blinded, double-dummy, positive parallel controlled, multi-centered clinical trial method, the tested group was treated by orally taken 3 capsules of ZHC (0.5 g/capsule) twice a day, and the control group was treated by orally taken Lotensin Tablet 1 tablet (10 mg/tab.) once a day. And all received the adiaphorous drug with the dosage-form mimic to that used in the tested group. The therapeutic course was 4 weeks for both groups.
RESULTSThe markedly effective rate and the total effective rate in reducing blood pressure was 58.65% and 79.81% respectively in the tested group, and 60.51% and 78.34% respectively in the control group; while the markedly effective rate and the total effective rate for alleviating TCM syndrome was 21.15% and 78.85% in the tested group, and 25.48% and 86.62% in the control group respectively. Comparisons between the two groups showed insignificant difference (P > 0.05).
CONCLUSIONZHC has good efficacy and is safety in treating hypertension.
Adult ; Aged ; Angiotensin-Converting Enzyme Inhibitors ; therapeutic use ; Benzazepines ; therapeutic use ; Blood Pressure ; drug effects ; Double-Blind Method ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Humans ; Hypertension ; drug therapy ; physiopathology ; Male ; Middle Aged ; Phytotherapy ; Syndrome ; Tablets ; Yin Deficiency ; drug therapy ; pathology
2.Effect of Fuzheng Xiaozhi Diet on the Comprehensive Functions of Stroke Patients with Hemiplegia
Ai-Hong WANG ; Gui-Hua XU ; Wei LIU ; Qiu-Di WU ; Kou-Ying LIU
Journal of Nanjing University of Traditional Chinese Medicine 2016;32(2):129-133
ABSTRACT:OBJECTIVE To explore the effect of Fuzheng Xiaozhi Diet(FXD)on comprehensives function of stroke patients with hemiplegia.METHODS 120 patients were randomly divided into two groups:the treatment group(60 cases) and the control group(60 cases).At the end of the study,there were 58 patients in the treatment group and 50 in the control group. Conventional treatment and care were given to both groups while Fuzheng Xiaozhi diet was added in the treatment group.Func-tional Comprehensive Assessment were used to assess the comprehensive function(Motor function and cognitive function) and the blood lipid level at T0,the end of three month's treatment(T1),the end of six month's treatment(T2),and the end of twelve month's treatment(T3).RESULTS There were significant differences in the main effects of intervention,the main effects of time on scores of motor,comprehensive functions,HDL and TC(P <0.05~0.01),and there were significant differ-ences in the main effects of time on scores of cognitive function and Blood lipid various indicators (P <0.05~0.01) between two groups,respectively.The scores of motor and comprehensive functions and in experiment group were higher than that in control group 3,6 and 12 months after intervention(P <0.05~0.01).The scores of cognitive function in experiment group were higher than that in control group 6 and 12 months after intervention(P <0.05).CONCLUSION FXD can significantly improve the motor function,the cognitive function,the comprehensive functions and Lipid levels in stroke patients with hemi-plegia.
3.Treatment of rheumatoid arthritis arthralgia by xiaoyan zhitong paste: a clinical observation.
Qiu-Ai KOU ; Liang LI ; Jin-Yuan YAO ; Yi-Jun WANG ; Wen-Hui MA ; Cai-Yun ZHOU ; Ding-Ya FANG
Chinese Journal of Integrated Traditional and Western Medicine 2013;33(10):1320-1327
OBJECTIVETo formulate a comprehensive treatment program for rheumatoid arthritis arthralgia by clinical observing the efficacy of Xiaoyan Zhitong Paste (XZP).
METHODSAdopted was stratified, block randomized, double-blinded, placebo parallel controlled method. Subjects were assigned to the treatment group and the placebo group. Those in the treatment group were treated by external application of XZP, one to two pastes each time, covering the painful area, exchange once per 24 h, with one-day interval during a 7-day consecutive medication, two 7-days of treatment consisting of one therapeutic course. XZP placebos were applied for those in the placebo group in the same medication way. Joint pain and VAS were taken as main indices for observing the clinical efficacy of XZP.
RESULTSThe improvement of the analgesic effect and the Chinese medical syndrome efficacy of XZP were superior to that of the placebo.
CONCLUSIONXZP showed obvious effect in treating rheumatoid arthritis arthralgia with no obvious adverse reaction.
Adult ; Arthralgia ; drug therapy ; Arthritis, Rheumatoid ; drug therapy ; Drugs, Chinese Herbal ; administration & dosage ; therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Phytotherapy ; methods
4.Mechanisms of Ersi Decoction on Rheumatoid Arthritis Rats Induced by Bovine Type Ⅱ Collagen-solution
Tian-yue MA ; Yi-mei FANG ; Gan-lin GUO ; Jia-xi YANG ; Bin YANG ; Yi-kun YANG ; Qiu-ai KOU
Chinese Journal of Experimental Traditional Medical Formulae 2022;28(5):38-45
ObjectiveTo observe that effect of Ersi decoction on rats with rheumatoid arthritis (RA) induced by using the complete Freund's adjuvant emulsion containing bovine type Ⅱ collagenand and elucidate underlying menchanisms involving to inhibit inflammation and joint synovial angiogenesis. MethodThe rat model of RA was established by immune induction with complete Freund's adjuvant emulsion containing bovine type Ⅱ collagen. All male SD rats were randomly divided into blank group, RA model group, methotrexate group(1.0 mg·kg-1), and low-, medium- and high-dose group(30,15,7.0 g·kg-1·d-1)of Ersi decoction, with 8 rats in each group. Except the blank group, rats in the methotrexate group and Ersi decoction groups were given corresponding doses of methotrexate and Ersi decoction after establishment of RA induced by strengthen immunity,respectively,and those in the model group and blank group received normal saline of equivalent volume,once a day for 28 days. After the administration, the degree of joint swelling of rats in each group was analyzed by joint swelling volume and index. The small animal ultrasound imaging system was used to detect the score and area of synovial hyperplasia of knee joint in right lower limb of rats and hematoxylin-eosin(HE)staining to observe the histomorphological changes in joint synovium of rats. The levels of tumor necrosis factor-α(TNF-α) and interleukin-1β(IL-1β) were measured by enzyme-linked immunosorbent assay(ELISA). Immunohistochemistry was employed to analyze the expression of CD31 and vascular endothelial growth factor receptor 2(VEGFR2) in in joint synovium. ResultCompared with the blank group, the model group demonstrated significant increase in joint swelling volume and index, inflammatory cytokines including TNF-α and IL-1β in serum, the score and area of synovial hyperplasia of knee joint in right lower limb, obvious pathological changes in the synovium and the expression of CD31 and VEGFR2 in joint synovium. Medium and high-dose Ersi decoction significantly alleviated the pathological changes of synovium tissue, attenuated joint swelling volume and index and decreased the expression of CD31 and VEGFR2 in joint synovium as compared with the model group. Moreover, high-dose Ersi decoction showed significantly lower levels of TNF-α and IL-1β in serum, and the score and area of synovial hyperplasia of knee joint in right lower limb. But medium-dose Ersi decoction only showed lower levels of TNF-α and area of synovial hyperplasia of knee joint. ConclusionErsi decoction could reduce synovial inflammation and hyperplasia through inhibiting synovial angiogenesis in rats with RA induced by bovine type Ⅱ collagen for achieving the effect of reducing RA joint damage, which provides an important reference for anti-RA of Ersi decoction in clinical application.